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Abstract
Taenia solium is endemic in Madagascar and presents a significant burden on the popula-
tion and the health system. The parasite cycles through humans who host the adult tape-
worm, and pigs that host the larval stages. Accidental infection of humans may occur with
the larval stages which encyst in the nervous central system causing neurocysticercosis, a
major cause of seizure disorders and a public health problem. One of the interventions to
facilitate the control of the disease is mass drug administration (MDA) of the human popula-
tion with taeniacide. Here we describe a pilot project conducted in Antanifotsy district of
Madagascar from 2015 to 2017 where three annual rounds of MDA (praziquantel, 10mg/Kg)
were undertaken in 52 villages. Changes in the prevalence of taeniasis were assessed
before, during and after the treatments. A total of 221,308 treatments were given to all eligi-
ble people above 5 years of age representing a 95% coverage of the targeted population.
No major adverse effects were notified related to the implementation of the MDA. The preva-
lence of taeniasis was measured using Kato-Katz and copro-antigen techniques. Analyses
undertaken combining the results of the Kato-Katz with copro-antigen, or using the Kato-
Katz results alone, showed that there was a significant reduction in taeniasis 4 months after
the last MDA, but 12 months later (16 months after the last MDA) the taeniasis prevalence
had returned to its original levels. Results of the pilot project emphasize the need of a multi-
sectorial One-Health approach for the sustained control of T. solium.
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Author summary
The parasite Taenia solium causes neurocysticercosis in humans in its larval stage and is
the main cause of seizure disorders in poor communities that keep pigs (the intermediate
host). Diagnosis and treatment of neurocysticercosis remains beyond the reach of the gen-
eral population in Madagascar. Prevention is therefore the most suitable strategy for com-
bating this disease. Mass drug administration (MDA) is used to treat communities for
several parasitic diseases such as schistosomiasis. Infection with the T. solium tapeworm
in people can be treated with MDA using praziquantel. Here, we conducted a pilot project
in Madagascar, giving over 220,000 treatments to people in 52 villages once per year, for 3
consecutive years. The effects on taeniasis seemed to be encouraging when assessed 4
months after finishing the treatment, but 16 months later, the parasite’s prevalence had
returned to its original level. MDA was effective in providing temporary control of taenia-
sis, but parasite transmission was not interrupted. With respect to T. solium, this high-
lights the need of incorporating other interventions such as vaccination and medication
in pigs, improved pig husbandry and meat inspection to tackle the whole cycle of the
parasite.
Introduction
Taenia solium has been known to be endemic in Madagascar since the early 20th century; por-
cine cysticercosis was described in 1901, and the first human cases were described in 1904 and
confirmed by autopsy in 1909 [1]. Molecular studies of T. solium from Madagascar found both
Asian (Indian subcontinent) and Afro-American genotypes to be widespread on the island,
suggesting that the parasite was established in Madagascar at least twice in the past 2000 years
[2–4].
The life cycle of T. solium involves humans and pigs; humans harbour the adult tapeworm
(developing taeniasis), and pigs harbour the larval stages (developing porcine cysticercosis).
Pigs are infected by ingesting T. solium eggs released with the faeces of humans harbouring the
tapeworm, and humans develop taeniasis after eating undercooked or raw infected pork. The
main clinical problems due to T. solium arise because humans may also be infected with the
parasite’s larval stage (cysticercus) by accidentally ingesting T. solium eggs. In humans, the cys-
ticerci commonly encyst in the brain and the nervous system, causing neurocysticercosis
(NCC). NCC is a frequent cause of seizures in countries in which the disease is endemic [5]
including Madagascar [6]. NCC is an important problem in many countries where sanitation
is poor, and pigs roam freely [7]. The conditions which favour T. solium transmission and cys-
ticercosis in humans are present in Madagascar, including poor basic sanitation, deficient
hygiene practices and free roaming pigs which have opportunities for contact with human
faeces.
T. solium continues to be a health problem in Madagascar [8] and a high endemicity of por-
cine cysticercosis has been recorded. From March 2013 to February 2014, meat inspection in
two abattoirs identified 3,219 pigs out of 68,432 as having cysticercosis, an overall prevalence
of 4.7%, adjusted to 21.03% when considering the sensitivity of the meat inspection [9].
Numerous cases of taeniasis were identified in Madagascar when Kato Katz tests on human
faecal samples were conducted for epidemiological studies of schistosomiasis and soil trans-
mitted helminths by the Ministry of Public Health in collaboration with the Pasteur Institute
during 2012–2016 (personal communication—Sylvia Ramiandrasoa). Of 114 districts sam-
pled, 53 were identified as having cases of human taeniasis. Pork is a major source of meat in
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most regions of Madagascar, whereas beef is rarely consumed. Similarly, cultural practices in
Madagascar do not include consumption of pig raw liver. For these reasons, the majority of
the cases of taeniasis identified in the country were believed to be T. solium and not Taenia
saginata (that includes cattle as intermediate host) or Taenia asiatica (that usually develops in
the liver of pigs). Cases of NCC continue to occur, and seropositivity in humans for T. solium
remains high. A serological survey of human cysticercosis including 4,375 samples between
1994–1999, using an ELISA test for screening and EITB (Enzyme-linked Immunoelectro
Transfer Blot) for confirmation, showed a prevalence varying from 7 to 21% in the different
provinces [10]. In 2013, a cysticercosis survey at the Antsirabe Hospital (Vakinankaratra
region) using a commercial Western Blot (LD Bio Diagnostic, Lyon, France) revealed 14.7%
seropositivity (35 positives out of 237) [11].
A diverse range of potential control tools are available for T. solium, and can be aimed at
humans and/or pigs. They include preventive chemotherapy for taeniasis, health promotion
and education, improvement of basic sanitation, pig vaccination and treatment, meat inspection
and improvement of pig rearing conditions [12, 13]. There is not a universal and validated strat-
egy for T. solium control that can be applicable to all countries or endemic areas. The tools used
and the frequency of their usage depend on the resources and capabilities locally available.
A national policy for the control of T. solium was launched in Madagascar in 2005 with the
objective of reducing the impact of cysticercosis. In 2011, preventive chemotherapy imple-
mented as mass drug administration (MDA) was conducted in three districts involving
approximately 240,000 people, but it was not possible to conduct a detailed evaluation of the
program’s effectiveness.
In presenting a rationale for investment and action for T. solium control in 2016, the World
Health Organization (WHO) emphasised that tools and approaches are available to facilitate
the control of T. solium in humans and animals and used Madagascar as one of the country
case examples identifying lessons, context and funding requirements [14].
The government and the Ministry of Public Health of Madagascar remain committed to
control the disease and to implement integrated approaches on the fight against neglected
tropical diseases. As part of that commitment, here we describe the evaluation of a pilot project
for the mass treatment of taeniasis conducted in Antanifotsy district of Madagascar from
2015–2018 with support from the WHO.
Materials and methods
Madagascar is an island country in the Indian Ocean, off the coast of East Africa. It has 22
regions, which are further subdivided into 116 districts. The district of Antanifotsy (Fig 1)
located in the Vakinankaratra region, was selected for the pilot project due to its high preva-
lence of taeniasis identified during helminthiasis/schistosomiasis surveys conducted by the
Ministry of Public Health and the Pasteur Institute. In 2011 the prevalence of taeniasis in vil-
lages of Antanifotsy ranged from 2.7 to 19.2%. This area is not endemic for schistosomiasis
and there has been no MDA conducted for schistosomiasis control. The district of Antanifotsy
comprises 12 communes and 248 fokontany (villages). In 2015 the total population of Antani-
fotsy was 401,706 with a density of 117 inhabitants/Km2. It is an agro-pastoralist area. Three
communes, in which the schools showed a higher prevalence of taeniasis during the schistoso-
miasis mapping, were targeted for the pilot trial (Ambatolahy, Ambohitompoina and Antsaha-
lava) with a total of 52 villages representing 94,862 inhabitants.
The objective of the pilot project was to reduce the prevalence of taeniasis to below 1% in
the three communes at least one year after three rounds of annual treatment (2015–2017) of
the population by MDA.
PLOS NEGLECTED TROPICAL DISEASES Impact of a 3-year MDA pilot project for taeniasis control in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008653 September 18, 2020 3 / 13
Ethics statement
Ethical authorisation was provided by the Ministry of Public Health of Madagascar (Ref.036/
MSANP/CE du 06/06/2015). Informed written consent was obtained from the head of the
households and measures were taken to ensure patient confidentiality.
Mass drug administration
The taenicide drug chosen was praziquantel [15, 16], which is available in Madagascar as it is
already used in other regions for control of schistosomiasis. Praziquantel was given as a single
dose at 10 mg/kg, which is the WHO recommended dose for taeniasis [15] and is lower than
the dose used for MDA for schistosomiasis (40 mg/kg). Adults and children over 5 years of age
were included in the MDA project. Community Health Agents (CHA) provided the treatment
(there are usually two CHA per village), and Health Agents (HA) of the Ministry of Public
Health acted as supervisors. Pregnant women and people with symptoms which might occur
in neurocysticercosis (a history of intense or chronic headache, seizures or epilepsy) were
excluded due to the potential of praziquantel to cross the blood-brain barrier and precipitate
adverse neurological effects due to an inflammatory response of the damaged cysts [17]. The
CHA are volunteers who are committed to work for the health of their communities. They
receive training in several areas of health and health programs. They are familiar with the com-
munity and likely to be aware of people in the area with epilepsy. They received specific train-
ing for identification of epilepsy cases prior to commencement of each MDA campaign.
The main activities conducted for the MDA were training of the CHA and HA, social mobi-
lisation (advocacy, materials developed for information, education and communication,
awareness campaigns, media coverage, official launch ceremony), treatment and supervision.
Adverse effects to the praziquantel medication were monitored actively and passively. Dur-
ing the 5–7 days over which the MDA administration occurred, the CHA would circulate
Fig 1. Map of the intervention area. a) Map of Madagascar showing Vakinankaratra region; b) Map of
Vakinankaratra region showing Antanifotsy district; c) The three communes targeted (and the number of villages
targeted in brackets): Ambatolahy (10), Ambohitompoina (26) and Antsahalava (16).
https://doi.org/10.1371/journal.pntd.0008653.g001
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through the villages and hamlets to identify any possible adverse reactions to the MDA. If a
CHA was notified of a reaction, it was recorded in the treatment and report cards, with the
evolution of the effects. Minor side effects (MSE) were defined as those that were mild and of
short duration, for example effects which disappeared spontaneously or after a brief period of
rest and having a drink of water. Major side effects included those which were intense, pro-
longed and needed medication or medical attention. MSE such as slight nausea and vomiting
or digestive disorders were handled by the CHA. Any more significant side-effect such as diz-
ziness, severe headache or seizures were to be referred immediately to the Health Centres, to
be dealt by medical personnel. The major side effects were to be reported to the Pharmacovigi-
lance Service of the Ministry of Health, and this was the responsibility of the HA, using the
pharmacovigilance sheets available at the Health Centres.
Impact evaluation
Cross-sectional surveys were conducted in the three communes by faecal examinations for the
presence of taeniasis in a sample of the population before starting the MDA (T0), after the first
MDA (T1) as well as 4 (T2) and 16 months (T3) after the final MDA. Examination of the faecal
samples was conducted by microscopy using the Kato-Katz technique and copro-antigen. The
protocol used for Kato-Katz was the one described by the WHO [18]. The copro-antigen tech-
nique used was as described by Somers et al [19] with reagents and training provided by the
Institute of Tropical Medicine, Antwerp, Belgium (ITM). Samples with an optical density
above 0.175 were considered positive. The tests were conducted at the Centre Hospitalier Uni-
versitaire–Joseph Ravoahangy Andrianavalona (CHU-JRA) with the support of ITM.
A sample size of 960 was calculated for the faecal examinations using StatCalc from Epi
Info™, taking into account that the population over 5 years of age in the 3 communes was
75,668 inhabitants, a taeniasis prevalence of 5.1% based on the results of a survey undertaken
in the area in 2011, a 95% confidence interval, an accepted error of 3%, a design effect of 4 and
an anticipated non-response level of 15%. Twenty villages from the three communes were
selected at random and 48 individuals were selected at random at each testing point for faecal
sampling in each village.
Differences in the prevalence of taeniasis were evaluated using the N-1 Chi-squared test
using WINPEPI [20, 21].
Timelines
The three rounds of MDA were conducted in December 2015, October 2016 and October
2017 (Fig 2). Monitoring surveys were undertaken before the start of the project (Baseline T0:
Nov 2015), after the first MDA (Interim evaluation T1: Sept 2016), after the 3rd MDA (T2: Feb-
ruary 2018) and a year later, in February 2019 (T3). Originally T3 was planned to be conducted
a year after the MDA (October 2018), but it was delayed due to a plague outbreak.
Results
A total of 208 CHA (the individuals who provided the treatment) and 13 HA (supervisors)
were trained. Advocacy material was developed and distributed including awareness posters,
campaign launch posters, flyers, banners, etc. Advocacy meetings were held with key stake-
holders in 2015, 2016 and 2017. They were all well attended, and the participant showed a high
level of interest.
A total of 221,308 treatments were given during the 3 MDA campaigns (Table 1). The pop-
ulation coverage over the 3 years was 95.64%. The coverage rate was calculated as the propor-
tion of the number of targeted people (>5 years of age) who received treatment in each round.
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Adverse side effects were monitored by the CHA and HA according to the project proto-
cols. During the three rounds of MDA, minor side effects (MSE) such as nausea and temporary
diarrhoea were noted in 0.37%, 0.25% and 0.22% of the persons treated for each round (Tables
2 and 3). The majority of MSE were digestive, and they resolved after drinking water and
ingesting some food. There were no notifications of major side effects.
Twenty villages were randomly selected for evaluation by examination of faecal samples.
Due to logistical issues, only 15 of the original villages selected and included in T0, were acces-
sible at T2 and T3, so an additional 5 randomly selected villages were used to replace those vil-
lages which became inaccessible to complete the sample size of 20 villages. During T1, only 5
of the original selected villages were accessible and so for that sampling period another 15 ran-
domly selected villages were included. For this reason, at each point 20 villages were included,
with 15 matched between T0, T2 and T3. Results of Kato-Katz and copro-antigen testing are
summarised in Tables 4 and 5.
Comparing the 20 villages, or only the 15 matched villages, the reduction of the prevalence
between T0 and T2 was statistically significant (P<0.001). However, between T0 and T3, there
was no significant difference (P>0.05).
Statistically significant reductions were observed between T0 and T2 when comparisons
were undertaken combining both Kato-Katz or copro-antigen positive samples, or when com-
paring only the results of the Kato-Katz test. Comparisons between T0 and T3 found no signif-
icant difference, either when comparing positive results for either Kato-Katz or copro-antigen
test, or Kato-Katz alone.
Twenty villages were also surveyed at T1 using the Kato-Katz and the copro-antigen test.
They were randomly selected within the area of the MDA; five of these villages coincided with
Fig 2. Timelines of the 3-year MDA pilot project for taeniasis control in Madagascar.
https://doi.org/10.1371/journal.pntd.0008653.g002
Table 1. Coverage of the 3-year MDA pilot project for taeniasis control in Madagascar.
Communes 1st MDA—2015 2nd MDA—2016 3rd MDA—2017 TOTAL
P T C (%) P T C (%) P T C (%) P T C (%)
Ambatolahy 16,172 15,303 94.63 16,857 16,308 96.74 17,301 17,005 98.29 50,330 48,616 96.59
Ambohitompoina 35,677 34,285 96.10 38,459 36,154 94.01 39,536 37,751 95.49 113,671 108,190 95.18
Antsahalava 21,773 20,284 93.16 22,496 21,546 95.78 23,128 22,672 98.03 67,397 64,502 95.70
Total 73,622 69,872 94.91 77,811 74,008 95.11 79,965 77,428 96.83 231,399 221,308 95.64
P: Total number of people > 5 years of age; T: Number of people treated; C: Coverage
https://doi.org/10.1371/journal.pntd.0008653.t001
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the villages also surveyed at T0, T2 and T3. The number of samples taken was 961, one sample
was Kato-Katz positive but copro-antigen negative, and 10 samples were Kato-Katz negative
but copro-antigen positive (Table 6). That is 1.14% of the samples were positive. Among the
five villages which were assessed at both T0 and the first post-treatment sampling (T1), there
were 14 cases of taeniasis with KK or copro-antigen at T0 while 2 positive cases were recorded
at T1.
Discussion and conclusions
Approximately 95% coverage of the population targeted at each round of MDA was achieved
thanks to the engagement of the local communities and the successful awareness and social
mobilisation campaigns. Three annual praziquantel treatments of the human population in 52
villages in Madagascar resulted in more than 80% reduction in the prevalence of taeniasis in
the treated communities when measured approximately 4 months after the third treatment.
However, the prevalence of taeniasis returned to a level similar to that seen prior to the first
MDA, when measured 16 months after the final MDA round.
Changes in the levels of taeniasis infection that were observed were similar when comparing
results from different diagnostic procedures and when including the total 20 villages sampled,
or the 15 matched villages between T0 and T2/T3. Recording samples as being positive using
either direct (Kato-Katz positive) or indirect (copro-antigen test positive) evidence of the pres-
ence of a tapeworm, or when only definitive evidence for the presence of a tapeworm was
included (i.e. Kato-Katz positive due to the presence of taeniid eggs in the faeces), led to similar
outcomes in terms of changes in taeniasis prevalence (Tables 4 and 5). Also, the results
observed when data from all 20 villages that were involved in the trial were included in the
analyses, or when comparisons were restricted to only the 15 villages which had matching data
Table 2. Minor side effects (MSE) recorded during a 3-year MDA pilot project for taeniasis control in Madagascar using praziquantel 10mg/kg in patients> 5 years
of age.
Communes MSE 1st MDA 2015 MSE 2nd MDA 2016
T D A 0 Total (%) T D A 0 Total (%)
Ambatolahy 15,303 41 8 14 63 (0.41%) 16,308 36 4 5 45 (0.28%)
Ambohitompoina 34,285 75 12 10 97 (0.28%) 36,154 57 17 8 82 (0.23%)
Antsahalava 20,284 67 8 27 102 (0.5%) 21,546 31 24 1 56 (0.26%)
Total 69,872 183 28 51 262 (0.37%) 74,008 124 45 14 183 (0.25%)
T: Number of people treated; D: Digestive side effects: nausea, vomits, abdominal pain and mild diarrhoea; A: Allergic reactions: urticaria, itching; O: Others such as
weakness.
https://doi.org/10.1371/journal.pntd.0008653.t002
Table 3. Minor side effects (MSE) recorded during a 3-year MDA pilot project for taeniasis control in Madagascar using praziquantel 10mg/kg in patients> 5 years
of age (continued from Table 2).
Communes MSE 3rd MDA 2017 MSE—TOTAL
T D A 0 Total (%) T D A 0 Total (%)
Ambatolahy 17,005 27 12 1 40 (0.24%) 48,616 104 24 20 148 (0.30%)
Ambohitompoina 37,751 48 17 9 74 (0.20%) 108,190 180 46 27 253 (0.23%)
Antsahalava 22,672 41 11 2 54 (0.24%) 64,502 139 43 30 212 (0.33%)
Total 77,428 116 40 12 168 (0.22%) 221,308 423 113 77 613 (0.28%)
T: Number of people treated; D: Digestive side effects: nausea, vomits, abdominal pain and mild diarrhoea; A: Allergic reactions: urticaria, itching; O: Others such as
weakness.
https://doi.org/10.1371/journal.pntd.0008653.t003
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at the start and the end of the pilot project, also led to similar outcomes in terms of changes in
the prevalence of taeniasis (Tables 4 and 5).
At the time of the initial post-MDA assessment (T1), five villages were assessed that had
also been assessed at T0. Among those five villages there were 14 presumptive cases of taeniasis
(Kato-Katz or copro-antigen positive) at T0 and only 2 positive cases recorded at T1. One was
Kato-Katz positive and the other only positive in the copro-antigen test. The assessment at T1
was undertaken approximately 9 months after treatment. These initial data suggested that the
MDA treatment was having a substantial impact on taeniasis in the communities.
Assessment T2 was undertaken approximately four months after the third MDA treat-
ments. The pre-patent period for T. solium is approximately eight weeks [22, 23]. Positivity in
copro-antigen tests occurs at approximately the time of patency [24]. For this reason, the
assessment undertaken at T2 gives an indication of the number of new infections acquired
only in the period within approximately two months after the last MDA. On this basis, the
occurrence of 5 new infections representing 0.68% of the population seen at T3 could be
extrapolated, over a 12-month period, to re-establishment of a prevalence of a 4.08% infection
over 12 months in the absence of further MDA, suggesting a relatively rapid re-establishment
of taeniasis infection. This estimate appears to have been corroborated by the assessment
undertaken at T3, 16 months after the last round of MDA, which confirmed that taeniasis lev-
els had returned to a similar prevalence to that seen prior to the start of MDA.
Among the faecal samples tested during the project at all times, more samples were detected
as being positive in the copro-antigen test than were detected by Kato-Katz (Table 6). In our
studies at T0, of 19 faecal samples that were tested and found to have taeniid eggs present
(Kato-Katz positive), only 7 (37%) were positive in the copro-antigen test, suggesting a sub-
stantially lower sensitivity for the test than that observed by Mwape et al. [25], but closer to the
results recorded from Vietnam where only 1 out of 7 (14%) Kato-Katz positive samples also
tested positive with the copro-antigen [26]. The number of Kato-Katz positive at T1 and T2 is
too low to analyse. Significantly different results were observed with the copro-antigen test
Table 4. Results of faecal testing for taeniasis during a pilot control program for T. solium in Madagascar. Results of Kato-Katz and copro-antigen tests on faecal sam-
ples before (T0), after the final round of MDA (T2) of the 3-year pilot project, and one year later (T3). Results are shown for the 20 total villages surveyed.
Time N KK+CA- KK+CA+ KK-CA+ Total KK or CA pos % KK or CA Pos Total KK pos only % KK pos
T0 960 12 7 28 47 4.90% 19 1.98%
T2 976 1 1 4 6� 0.61% 2� 0.20%
T3 960 1 9 30 40 4.17% 10 1.04%
KK: Kato-Katz; CA: Copro-antigen; pos: positive
� statistically significant difference in the proportion compared to T0
https://doi.org/10.1371/journal.pntd.0008653.t004
Table 5. Results of faecal testing for taeniasis during a pilot control program for T. solium in Madagascar. Results of Kato-Katz and copro-antigen tests on faecal sam-
ples before (T0), after the final round of MDA (T2) of the 3-year pilot project, and one year later (T3). Results are shown for the 15 villages matched between T0, T2 and
T3.
Time N KK+CA- KK+CA+ KK-CA+ Total KK or CA pos % KK or CA Pos Total KK pos only % KK pos
T0 720 8 5 18 31 4.31% 13 1.81%
T2 733 1 1 3 5� 0.68% 2� 0.27%
T3 720 0 7 25 32 4.44% 7 0.97%
KK: Kato-Katz; CA: Copro-antigen; pos: positive
� statistically significant difference in the proportion compared to T0
https://doi.org/10.1371/journal.pntd.0008653.t005
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which were conducted at T3 in comparison to the results of T0 (T0; P = 0.008, Fisher’s Exact
Test). This change in the test’s performance might be related to a change in the reagents used
in the test, which incorporates a polyclonal rabbit anti-Taenia antiserum [25], as different
batches were used at each testing time. These results emphasize the difficulties in conducting
copro-antigen tests for taeniasis as there are no commercial tests available, and the validation
and quality control of in-house produced reagents is complex. Of 89 faecal samples that tested
positive by the coproantigen test, only 17 (19%) were also positive for the presence of taeniid
eggs. This is not unexpected because Kato-Katz is known to have a relatively low sensitivity for
detection of taeniasis [26, 27]. Nevertheless, despite its low sensitivity the Kato-Katz test alone
was able to detect significant differences in the prevalence of taeniasis given the prevalence of
taeniasis in the study population and the sample size.
This study did not differentiate which species of Taenia was responsible for causing taenia-
sis. Three species cause taeniasis in humans–T. solium, T. saginata and T. asiatica. T. saginata
has not been reported in Madagascar and it is unclear whether Taenia asiatica occurs in Mada-
gascar. Fan and colleagues [28] found that pigs experimentally infected with eggs of a Taenia
tapeworm that was described as having originated in Madagascar developed into cysts in the
liver. This has been interpreted as providing evidence for the presence of T. asiatica in Mada-
gascar. However, the provenance of the tapeworm used by Fan and his colleagues is equivocal.
By comparison, there are a number of reports of T. solium from Madagascar, in both humans
and animals (pig) [6, 8, 9]. For these reasons, we consider that many of the cases of taeniasis
that were detected, were due to T. solium. Nevertheless, the praziquantel MDA that was imple-
mented in this trial would have been effective against all three species causing human taeniasis.
There were no major side effects reported after treatment with praziquantel at 10mg/kg.
This could be because all suspicious cases of neurocysticercosis were excluded from treatment
and/or because of the dose of praziquantel that was used. The praziquantel dose commonly
used for taeniasis, and that was used here, is 10mg/kg. This is much lower than the dose levels
used for the treatment of cysticercosis when it is desired that the drug crosses the blood-brain
barrier and affects the parasite (50mg/kg daily in three divided doses for 14–30 days, or 25mg/
kg given two-hourly in a single day scheme, or combined with albendazole at 50 mg/kg for 10
days) [15, 29, 30]. A recent review on drugs used for preventive chemotherapy for taeniasis
[16], did not find evidence of severe side effects associated to the use of praziquantel at this
dose. There has been a limited number of case reports of adverse events in neurocysticercosis
patients, but it is unclear whether these reactions were coincidental occurrences. However,
due to the limited evidence, it concluded that praziquantel at 10mg/kg can be considered for
mass drug administration of taeniasis, but active monitoring of side effects is warranted to
minimise concerns and to add to the evidence of its safety. Several authors have evaluated the
reduction in taeniasis in human populations following MDA with a taeniacide (reviewed by
Table 6. Results of all faecal samples which tested positive during the MDA pilot control program for T. solium in
Madagascar. Results shown for the 20 villages tested at each time-point. Different batches of reagents were used for
the copro-antigen tests undertaken at each time point.
Time KK+CA- KK+CA+ KK-CA+ Total KK+ %KK+, also CA+
T0 12 7 28 19 37%
T1 1 0 10 1 0%
T2 1 1 4 2 50%
T3 1 9 30 10 90%
KK: Kato-Katz; CA: Copro-antigen; +: positive; -: negative
https://doi.org/10.1371/journal.pntd.0008653.t006
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Lightowlers [12]). Most trials in which MDA alone has been implemented have been under-
taken over a small number of years and sustained impacts on T. solium transmission have not
been demonstrated. Mathematical modelling published by Brae et al. [31] found that annual
MDA with taeniacide with a coverage of 75% of the human population achieved a 50–60%
reduction in the prevalence of T. solium taeniasis when assessed 12 months after completion of
4 annual rounds of MDA. Our results in Madagascar after three annual rounds of MDA,
assessed 16 months after the final MDA, suggest that the impact on taeniasis was less than the
modelling may have predicted. More recent modelling [32] of T. solium transmission using a
coverage of 80% of the human population, suggests that annual MDA in humans for as long as
10 years would be predicted to be slow in reducing the prevalence of taeniasis, whereas bian-
nual MDA for 10 years could achieve elimination of T. solium transmission with a probability
of>80%.
In the case of T. solium, the impact of taeniasis treatments alone as a control measure is
hampered by the continued existence of infections in the pig population which serve as a
source for re-establishment of taeniasis in humans. Mathematical modelling of T. solium trans-
mission and its control [31–34], and a logical model of T. solium control [35], suggest that a
combination of interventions in the pig population (vaccination and medication) as well as
MDA application of taeniacide in humans would have a more rapid, more substantial and lon-
ger lasting impact on T. solium transmission than the use of taeniacides alone. The treatment
of human taeniasis, and the interventions in pigs are described as core “rapid impact” inter-
ventions, but other supportive measures such as improved sanitation, community education,
pig husbandry and meat inspection can also play an important role [36]. At national level, the
control of T. solium requires not only technical activities, but also a socioeconomic approach
and political engagement.
While the use of MDA for taeniasis in the Madagascar communities described here did
achieve a short term reduction in the prevalence of taeniasis to�1%, re-establishment of taeni-
asis after the cessation of treatments indicates that other control measures would be needed in
order to bring about a sustained reduction in Taenia transmission. With respect to T. solium,
control trials are warranted incorporating MDA together with other control measures target-
ing infections in the pig population towards implementation of a national cysticercosis control
program.
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